Nami Surgical has secured £3.4m in additional funding to advance its ultrasonic technology for robotic-assisted surgery, including a £2m investment from the Scottish National Investment Bank.
Founded in 2021 as a spin-out from the University of Glasgow, Nami develops ultrasonic surgical instruments designed for integration into robotic systems.
The investment will support the expansion of Nami’s engineering and commercial teams, including five additional jobs at its headquarters in Hillington, southwest Glasgow.
The funding round extension also includes continued backing from existing investors Eos Advisory, Scottish Enterprise and the Investment Fund for Scotland, which is managed by Maven Capital Partners and delivered by the British Business Bank.
How the ultrasonic technology works
Ultrasonic scalpels use high-frequency vibrations to cut tissue and seal blood vessels simultaneously.
Conventional ultrasonic surgical instruments can be difficult to integrate into robotic systems because of their size and rigidity.
Nami has developed a patented platform that miniaturises the ultrasonic transducer, allowing the scalpel to articulate within wristed robotic instruments while retaining its cutting and sealing capabilities.
The company is developing partnerships with businesses across the global surgical robotics market as it progresses towards commercialisation.
Nami’s recent developments include the appointment of Chief Executive Nikki Palfrey in January 2026 and achieving ISO 13485 certification in the same month.
The international standard specifies requirements for quality management systems used by medical device manufacturers.
“Robotic-assisted surgery is a rapidly growing field in the medtech industry worldwide. Nami’s innovative IP introduces new capabilities to the field,” said Ailsa Young, Investment Director at the Scottish National Investment Bank.
She added that the investment would support skilled job creation in Glasgow and help retain intellectual property and technology in Scotland.
Nami said the funding would enable it to strengthen its engineering capabilities, accelerate development of its ultrasonic platform and build partnerships with companies across the surgical robotics sector.
“[We are] moving from demonstrating the potential of our technology to building the capabilities and partnerships needed to bring it into the surgical environment,” said Nikki Palfrey, Chief Executive of Nami Surgical.
Our ambition is to establish Nami as a key technology partner in the global robotic surgery market.
